WILMINGTON, Del. & nicorette inhaler --()-- Extab Corporation ("Extab") a clinical phase biopharmaceutical business with a focus on smoking cigarettes cessation, today revealed the results of a cost effectiveness research study published in the peer examined journal, Nicotine and Tobacco Research Study. These information are based upon the results of the Tabex Smoking Cessation ("TASC") 740-patient pivotal trial, which were released in the New England Journal of Medicine on September 29, 2011.
Quit rates were verified by exhaled carbon monoxide levels. The trial revealed a highly statistically substantial result with a Risk Ratio of 3. 4 (p.
0 
Star